Editorial: The safety and efficacy of ustekinumab in anti-TNF α refractory pediatric inflammatory bowel disease.
作者信息
Ho Katelynn K, Suskind David L, Wahbeh Ghassan T
机构信息
Pediatric Gastroenterology, Hepatology and Nutrition, Seattle Children's Hospital - University of Washington, Seattle, WA, United States.
出版信息
Saudi J Gastroenterol. 2025 Mar 1;31(2):51-52. doi: 10.4103/sjg.sjg_384_24. Epub 2025 Mar 12.
Abstract
摘要
相似文献
1
Editorial: The safety and efficacy of ustekinumab in anti-TNF α refractory pediatric inflammatory bowel disease.社论：优特克单抗治疗抗TNFα难治性儿童炎症性肠病的安全性和有效性
Saudi J Gastroenterol. 2025 Mar 1;31(2):51-52. doi: 10.4103/sjg.sjg_384_24. Epub 2025 Mar 12.
2
Augmented ustekinumab dosing is needed to achieve clinical response in patients with anti-TNF refractory pediatric Crohn's disease: a retrospective chart review.增效乌司奴单抗给药对于治疗抗 TNF 治疗抵抗的儿童克罗恩病患者至关重要：一项回顾性图表研究。
F1000Res. 2020 Apr 30;9:316. doi: 10.12688/f1000research.22673.2. eCollection 2020.
3
Ustekinumab Use in Pediatric Inflammatory Bowel Disease: A French Multicenter Study From the Pediatric GETAID.乌司奴单抗在儿童炎症性肠病中的应用：法国儿科 GETAID 的一项多中心研究。
J Pediatr Gastroenterol Nutr. 2023 Jun 1;76(6):763-770. doi: 10.1097/MPG.0000000000003758. Epub 2023 Mar 8.
4
Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease.与抗TNF药物相比，维多珠单抗和优特克单抗在炎症性肠病孕妇中的安全性。
Clin Gastroenterol Hepatol. 2025 Jan;23(1):144-153.e22. doi: 10.1016/j.cgh.2023.12.029. Epub 2024 Jan 8.
5
Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn's disease patients: a systematic review and meta-analysis.优特克单抗在肿瘤坏死因子-α难治性克罗恩病患者诱导治疗中的疗效与安全性：一项系统评价和荟萃分析。
J Comp Eff Res. 2017 Oct;6(7):601-612. doi: 10.2217/cer-2017-0022. Epub 2017 Jun 29.
6
Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children's hospital in Japan.日本一家三级儿童医院中用于儿童和青少年炎症性肠病的优特克单抗。
J Gastroenterol Hepatol. 2021 Jan;36(1):125-130. doi: 10.1111/jgh.15128. Epub 2020 Jun 29.
7
Comparative risk of serious infections and tuberculosis in Korean patients with inflammatory bowel disease treated with non-anti-TNF biologics or anti-TNF-α agents: a nationwide population-based cohort study.接受非抗TNF生物制剂或抗TNF-α药物治疗的韩国炎症性肠病患者发生严重感染和结核病的比较风险：一项基于全国人群的队列研究。
Therap Adv Gastroenterol. 2024 Jul 31;17:17562848241265013. doi: 10.1177/17562848241265013. eCollection 2024.
8
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.皮下注射乌司奴单抗可为三分之二对肿瘤坏死因子拮抗剂治疗抵抗的克罗恩病患者带来临床获益。
Clin Gastroenterol Hepatol. 2016 Feb;14(2):242-50.e1-2. doi: 10.1016/j.cgh.2015.09.018. Epub 2015 Sep 30.
9
Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn's Disease: A Review of Comparative Effectiveness Studies.抗TNF药物治疗克罗恩病失败后使用优特克单抗或维多珠单抗：比较有效性研究综述
J Clin Med. 2024 Apr 10;13(8):2187. doi: 10.3390/jcm13082187.
10
Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.炎症性肠病难治状态背后的药效学机制。
BMC Gastroenterol. 2022 Nov 17;22(1):464. doi: 10.1186/s12876-022-02559-5.
本文引用的文献
1
Biomarkers predicting the effect of anti-TNF treatment in paediatric and adult inflammatory bowel disease.预测抗 TNF 治疗在儿科和成人炎症性肠病中疗效的生物标志物。
J Pediatr Gastroenterol Nutr. 2024 Jul;79(1):62-75. doi: 10.1002/jpn3.12221. Epub 2024 May 2.
2
Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study.优特克单抗治疗难治性炎症性肠病青年患者的临床疗效与安全性：一项回顾性队列研究。
Saudi J Gastroenterol. 2025 Mar 1;31(2):59-67. doi: 10.4103/sjg.sjg_7_24. Epub 2024 Apr 10.
3
Paradoxical Psoriasis Induced by Ustekinumab: A Comprehensive Review and Case Report.乌司奴单抗诱导的矛盾性银屑病：全面综述及病例报告。
Medicina (Kaunas). 2024 Jan 6;60(1):106. doi: 10.3390/medicina60010106.
4
Ustekinumab Use in Pediatric Inflammatory Bowel Disease: A French Multicenter Study From the Pediatric GETAID.乌司奴单抗在儿童炎症性肠病中的应用：法国儿科 GETAID 的一项多中心研究。
J Pediatr Gastroenterol Nutr. 2023 Jun 1;76(6):763-770. doi: 10.1097/MPG.0000000000003758. Epub 2023 Mar 8.
5
Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.阿达木单抗治疗中重度溃疡性结肠炎儿科患者的疗效和安全性（ENVISION I）：一项随机、对照、3 期研究。
Lancet Gastroenterol Hepatol. 2021 Aug;6(8):616-627. doi: 10.1016/S2468-1253(21)00142-4. Epub 2021 Jun 19.
6
Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study.乌司奴单抗治疗中重度活动期克罗恩病儿科患者的药代动力学、安全性和疗效：UniStar 研究的结果。
J Crohns Colitis. 2021 Nov 8;15(11):1931-1942. doi: 10.1093/ecco-jcc/jjab089.
7
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.STRIDE-II：炎症性肠病（STRIDE）国际研究组织（IOIBD）治疗靶点选择更新：确定炎症性肠病靶向治疗策略的治疗目标。
Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031. Epub 2021 Feb 19.
8
Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center.在一家三级儿童炎症性肠病护理中心，乌司奴单抗在儿童和青年中的真实世界应用经验。
J Pediatr Gastroenterol Nutr. 2019 Jul;69(1):61-67. doi: 10.1097/MPG.0000000000002362.
9
Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study.使用乌司奴单抗治疗儿童克罗恩病患者的管理：一项多中心队列研究。
J Crohns Colitis. 2019 Apr 26;13(5):578-584. doi: 10.1093/ecco-jcc/jjy206.
10
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.乌司奴单抗诱导和维持治疗克罗恩病。
N Engl J Med. 2016 Nov 17;375(20):1946-1960. doi: 10.1056/NEJMoa1602773.
Zotero 插件